
Sign up to save your podcasts
Or


A woman's public coverage for cancer drug Keytruda was denied, largely, it seems, on the basis that too few cancer patients have survived long enough to justify coverage beyond two years.
Guest: Richard Zussman - Global News Legislative Reporter
Learn more about your ad choices. Visit megaphone.fm/adchoices
By CKNW / CuriouscastA woman's public coverage for cancer drug Keytruda was denied, largely, it seems, on the basis that too few cancer patients have survived long enough to justify coverage beyond two years.
Guest: Richard Zussman - Global News Legislative Reporter
Learn more about your ad choices. Visit megaphone.fm/adchoices

15,489 Listeners

37,206 Listeners

204 Listeners

81 Listeners

4 Listeners

3 Listeners

4 Listeners

1 Listeners

0 Listeners

0 Listeners

92 Listeners

220 Listeners

73 Listeners

555 Listeners

13,704 Listeners

97 Listeners

1,727 Listeners

47,562 Listeners

22 Listeners

5 Listeners

5 Listeners

5 Listeners

10 Listeners

596 Listeners

2 Listeners

106 Listeners

60 Listeners

10,716 Listeners

41 Listeners

1 Listeners

0 Listeners

39 Listeners

4 Listeners